Hence, HDAC inhibitors have been well established as anti-tumor drugs for T cell lymphoma, multiple myeloma, non-small lung cancer, and so forth, with/without combination therapy such as bortezomib and dexamethasone. Here, HDAC9 is linked to T-cell non-Hodgkin lymphoma.